The synthetic biology concept fluctuated and rebounded in early trading. Sunda Biotech went up and down, while Boen Group, Kyodo Pharmaceuticals, Fujilai, and Azure Biotech followed suit. According to the news, Beijing released the “Beijing Action Plan to Accelerate Collaborative Innovation in Medicine and Health (2024-2026)”. The “Action Plan” proposes the deployment of “nuclear explosion point” projects in cutting-edge technology fields such as cell-gene therapy, brain-computer interface, and synthetic biology.
合成生物概念震荡反弹 圣达生物涨停
The synthetic biology concept shook and rebounded, and Sunda Biotech went up and down
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.